– Enhanced features extend automated insulin delivery (AID) to people ages 2 years and older with type 1 diabetes and adults with type 2 diabetes – Control-IQ+ automated insulin delivery technology ...
SAN DIEGO--(BUSINESS WIRE)-- Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a leading insulin delivery and diabetes technology company, today announced that its next-generation automated insulin delivery ...
Tandem Diabetes Care has received approval from the US Food and Drug Administration (FDA) for its Control-IQ+ automated insulin delivery technology to be used during pregnancy in individuals with type ...
The FDA announced Friday a De Novo clearance for an interoperable automated glycemic controller device for use in a hybrid closed-loop diabetes management system. Tandem Diabetes Care’s Control-IQ ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results